🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Baoding
Clinical trial register · China

Clinical Trials in Baoding, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Peking University3 Tasly Pharmaceutical Group Co., Ltd3 Hoffmann-La Roche3 BioNTech SE3
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Baoding

84 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
NCT07683806Seborrheic Dermatitis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Baoding, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu, Chifeng
2026-08-24
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Recruiting
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
NCT07711262Seasonal Allergic Rhinitis
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Phase 3
550
Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Baotou, Chifeng, Yinchuan, Jinan
2026-08-18
Recruiting
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
NCT07678931Seasonal Allergic Rhinitis (SAR)
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Not yet open
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
NCT07712692High-grade Squamous Intraepithelial Lesion (HSIL)
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
156
Beijing, Chongqing, Lanzhou, Baoding, Zhengzhou, Nanjing, Changchun, Jinan
2026-08-01
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248Primary Immune Thrombocytopenia
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Recruiting
Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
NCT07338175Intracerebral Hemorrhage
Beijing Tiantan Hospital
Phase 3
1,192
Beijing, Chongqing, Guangzhou, Baoding, Zhangjiakou, Zunhua, Mengzhou, Nanle
2026-04-02
Recruiting
Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
NCT07480525Depression - Major Depressive Disorder
Peking University
Not applicable
200
Beijing, Baoding, Shijiazhuang, Shenyang, Jinan
2026-03-20
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
NCT07398859Seasonal Allergic Rhinitis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
High-flow Nasal Cannula Versus Conventional Oxygen During Awake Tracheal Intubation With Difficult Airways
NCT07384494Awake Tracheal Intubation, Difficult Airway
Wenxian Li
Not applicable
336
Wuwei, Shenzhen, Baoding, Pizhou, Shanghai, Neijiang
2026-02-04
Recruiting
Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
NCT07018375Chronic Postsurgical Pain
Tianjin Medical University General Hospital
Phase 4
320
Baoding, Tangshan, Tianjin
2026-01-06
Not yet open
Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification
NCT07199101Radiation Dose Reduction
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
NCT07169331Waldenström's Macroglobulinemia
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Not yet open
Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes
NCT07198932Type 2 Diabetes
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
438
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Recruiting
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Hefei, Fuzhou, Guangzhou, Baoding, Wuhan, Changsha, Nanjing, Dalian
2025-08-05
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Not yet open
Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
NCT06920706Post-stroke Depression, Remote Ischemic Conditioning
Xuanwu Hospital, Beijing
Not applicable
240
Tongren, Baoding, Jilin City, Jincheng, Beijing
2025-04-10
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
NCT07087223Non Small Cell Lung Cancer NSCLC
Peking University Cancer Hospital & Institute
Phase 1/2
42
Neimeng, Baoding, Baotou, Beijing, Dalian, Tianjin
2025-04-08
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Changchun, Hangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-01-07
Not yet open
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
NCT06753890Diarrhea-predominant Irritable Boewl Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Recruiting
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple
Peking Union Medical College Hospital
Phase 4
1,504
Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong
2024-12-01
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 3
744
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
Active, closed
Effects of Parent-Adolescent Joint Interventions for Adolescents With Adverse Childhood Experiences
NCT06619821Stress, Emotional, Stress-related Mental Disorders, Adverse Childhood Experiences
Peking University
Not applicable
3,000
Baoding
2024-09-27
Active, closed
Effects of Parent-Adolescent Joint I-Interventions for Adolescents with Adverse Childhood Experiences
NCT06650696Stress-related Problem, Stress, Emotional
Peking University
Not applicable
200
Baoding
2024-09-27
Active, closed
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06635447Breast Cancer
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Recruiting
Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)
NCT06429774Traumatic Brain Injury
Beijing Tiantan Hospital
Observational
2,000
Beijing, Baoding, Cangzhou, Chengde, Handan, Langfang, Qinhuangdao, Shijiazhuang
2024-08-01
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Hyperplasia of Mammary Glands
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
pBFS Guided rTMS Over Cognitive Control Network for ASD
NCT06255535Autism Spectrum Disorder
Changping Laboratory
Not applicable
215
Fuzhou, Baoding, Xi'an, Jining, Linyi
2024-04-01
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Recruiting
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
NCT06758557Advanced NSCLC, Advanced Endometrial Cancer
Huabo Biopharm Co., Ltd.
Phase 1/2
282
Baoding, Harbin, Luoyang, Zhengzhou, Lianyungang, Shenyang, Jinan, Linyi
2024-01-31
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Active, closed
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06009861Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
A Study of Telitacicept in Lupus Nephritis
NCT05680480Lupus Nephritis
RemeGen Co., Ltd.
Phase 2
120
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Liuzhou, Guiyang, Baoding
2023-04-17
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Recruiting
SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
NCT05583773Heart Failure
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
BeiGene
Phase 2
400
Hefei, Beijing, Fuzhou, Baoding, Harbin, Zhengzhou, Wuhan, Nantong
2023-03-07
Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
NCT05607498Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase 1
150
Changsha, Baoding, Beijing, Bengbu, Guangzhou, Harbin, Shandong, Tianjin
2023-03-01
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Active, closed
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
NCT07226752Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Baoding, Beijing, Changsha, Chengdu, Deyang, Guangzhou, Hangzhou, Hefei
2022-09-15
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Active, closed
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
NCT05246514HER2-mutant Non-Small Cell Lung Cancer
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Active, closed
Long-term Efficacy and Safety Study of GV-971
NCT05181475Alzheimer Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922Hematologic Malignancies
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Baoding, Beijing, Changchun, Changsha, Dalian, Foshan, Fuzhou, Guangzhou
2020-07-24
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Baoding, Beijing, Changchun, Chongqing, Dalian, Foshan, Gongshu District, Guangzhou
2020-04-16
Active, closed
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT04208347Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital
Phase 2/3
580
Baoding, Beijing, Changsha, Changzhi, Chengdu, Guiyang, Haikou, Hangzhou
2019-12-18
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery
NCT03012971Elderly, Surgery, Analgesia, Dexmedetomidine
Peking University First Hospital
Not applicable
1,500
Beijing, Chongqing, Guiyang, Baoding, Changsha, Xi'an, Qingdao, Taiyuan
2017-01-06
Rows per page Showing 1–84 of 84
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/baoding

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 84 of those studies with a site in Baoding.

How many clinical trials are recruiting in Baoding?

48 of the 84 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Baoding), 84 studies
PhaseStudiesRecruitingShare
Phase 3381845.2%
Phase 211513.1%
Not applicable10511.9%
Phase 1/210911.9%
Phase 4536%
Observational434.8%
Phase 1333.6%
Phase 2/3323.6%

Most active sponsors

Lead sponsors with the most studies (Baoding)
Lead sponsorStudiesRecruiting
AstraZeneca155
Betta Pharmaceuticals Co., Ltd.32
BioNTech SE33
Bristol-Myers Squibb32
Hoffmann-La Roche31
Peking University31
Tasly Pharmaceutical Group Co., Ltd32
BeiGene20
Beijing Tiantan Hospital22
Capital Medical University22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.